RELIEF THERAPEUTICS S/ADR - RLFTY STOCK NEWS

Relief Therapeutics has announced the launch of its new PKU GOLIKE BARs in Europe, designed for patients with phenylketonuria (PKU). These prolonged-release amino acid medical foods come in tropical and red fruit flavors and are made with natural ingredients. Each box contains either 20 bars with 5g protein or 10 bars with 10g protein. The company has eliminated exposure to Credit Suisse and has no funds with closed U.S. banks, mitigating risks from recent banking sector issues. PKU affects over 450,000 patients globally, necessitating strict dietary management to avoid severe health consequences.

Acer Therapeutics reports that preliminary launch activities for OLPRUVA™ are progressing well, with commercial and medical teams being built to support the U.S. launch expected in Q2 2023. The drug is anticipated to be available by early July 2023. Acer has introduced the OLPRUVA™ Navigator service to assist patients and is negotiating access with major payers. The pricing strategy aims for a competitive position, significantly lower than current products like RAVICTI®. Acer will also present a survey on treatment preferences for urea cycle disorders at SIMD 2023.

Relief Therapeutics (OTCQB:RLFTF, OTCQB:RLFTY) announced the U.S. availability of PKU GOLIKE™ bars on Rare Disease Day 2023. These bars are designed for patients with phenylketonuria (PKU), a rare metabolic disorder affecting over 450,000 globally. Developed over four years with input from patients, the bars are available in tropical and red fruit flavors, using Physiomimic™ technology for improved absorption and taste. Each bar contains 5 g or 10 g protein equivalent, meeting dietary needs while limiting phenylalanine intake to under 15 mg per bar. The initiative aims to enhance compliance and address the dietary challenges faced by PKU patients.

Relief Therapeutics has begun enrolling patients in a proof-of-concept study for RLF-TD011, targeting epidermolysis bullosa (EB), a severe skin condition. The study aims to treat up to 17 patients with dystrophic or junctional EB and evaluate the skin microbiome's response to the treatment. RLF-TD011 is a sprayable solution designed for self-administration that aims to reduce infection rates and improve wound healing. The study will last eight weeks, with a follow-up period of four weeks. The potential market for EB treatments is estimated to exceed $1 billion.

Relief Therapeutics has announced a strategic update concerning its financing efforts, opting to withdraw a prior SEC registration statement to explore non-dilutive funding options. This move aims to facilitate a potential listing on the Nasdaq. The company plans a reverse stock split, pending shareholder approval, to enhance its appeal to investors. The proposed reverse split is part of a broader initiative to improve the company's public perception and reduce the number of outstanding shares, which currently stems from past mergers. Relief is focused on treating rare diseases and aims to advance its innovative pipeline, including partnerships for metabolic disorder treatments.

Relief Therapeutics Holding announced independent IRB approval for a trial of RLF-TD011 as an adjunctive treatment for cutaneous T-cell lymphoma (CTCL). This proof-of-concept study, led by Dr. Alan Zhou at Northwestern University, aims to assess the effects of RLF-TD011, a hypochlorous acid topical spray, on CTCL lesions over an eight-week period with 30 participants. Given the challenging prognosis of CTCL, where advanced cases have a five-year survival rate of just 24%, this study represents a critical development pathway for RLF-TD011, with potential implications for FDA and EMA submissions for this unmet medical need.

Relief Therapeutics Holding SA has filed Amendment No. 2 to its Registration Statement on Form F-1 with the SEC, proposing an offering of up to 833,333,200 ordinary shares as American Depositary Shares (ADSs). The preliminary prospectus includes warrants for an additional 625,000,000 shares. Underwriters may also purchase an extra 125,000,000 shares and warrants. The terms of the offering remain uncertain, pending finalization in a future amendment. The effectiveness of the registration statement and completion of the offering are not guaranteed, affecting potential investor interest.

Relief Therapeutics and NRx Pharmaceuticals have finalized settlement agreements resolving litigation between them. Key outcomes include Relief acquiring all assets related to the aviptadil development program, including regulatory filings and clinical data. Relief will now exclusively develop and commercialize aviptadil, continuing its Right to Try Program for two years. Moreover, Relief will make milestone payments to NeuroRx for commercial approval and pay royalties, capped at $30 million. The companies have agreed not to compete in aviptadil development.

Relief Therapeutics Holding SA will present at the 15th Annual Biotech Showcase and host investor meetings on January 9-10, 2023, in San Francisco. CEO Jack Weinstein will provide insights into the company’s rare disease portfolio and commercial strategy. The Biotech Showcase presentation is scheduled for January 10 at 3:30 PM PST. The company focuses on developing novel treatments for rare diseases and holds a diverse pipeline, including products for phenylketonuria and epidermolysis bullosa.